Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesBeginning Cash BalanceBeginning Cash BalanceCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Summit Therapeutics (SMMT) Shares Issued (2016 - 2025)

Summit Therapeutics filings provide 12 years of Shares Issued readings, the most recent being -$1.7 million for Q4 2025.

  • Quarterly Shares Issued fell 103.76% to -$1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5000.0 through Mar 2026, down 100.01% year-over-year, with the annual reading at $5.7 million for FY2025, 106.62% up from the prior year.
  • Shares Issued hit -$1.7 million in Q4 2025 for Summit Therapeutics, down from $1.7 million in the prior quarter.
  • Across five years, Shares Issued topped out at $100.0 million in Q3 2022 and bottomed at -$99.6 million in Q4 2022.
  • Average Shares Issued over 5 years is $10.3 million, with a median of $730000.0 recorded in 2021.
  • The largest annual shift saw Shares Issued skyrocketed 23225.39% in 2021 before it tumbled 248.13% in 2023.
  • Summit Therapeutics' Shares Issued stood at $73.1 million in 2021, then plummeted by 236.19% to -$99.6 million in 2022, then soared by 105.02% to $5.0 million in 2023, then skyrocketed by 784.46% to $44.2 million in 2024, then tumbled by 103.76% to -$1.7 million in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Shares Issued are -$1.7 million (Q4 2025), $1.7 million (Q2 2025), and $5.7 million (Q1 2025).